These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 20876380)
21. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. Lee KW; Lee JM; Jung KS J Korean Med Sci; 2001 Oct; 16(5):537-43. PubMed ID: 11641519 [TBL] [Abstract][Full Text] [Related]
22. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128 [TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. Huy NQ; Lucie C; Hoa TTT; Hung NV; Lan NTN; Son NT; Nhung NV; Anh DD; Anne-Laure B; Van Anh NT Emerg Microbes Infect; 2017 Oct; 6(10):e86. PubMed ID: 29018250 [TBL] [Abstract][Full Text] [Related]
24. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262 [TBL] [Abstract][Full Text] [Related]
25. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M. tuberculosis fatty acid synthase I. Sayahi H; Pugliese KM; Zimhony O; Jacobs WR; Shekhtman A; Welch JT Chem Biodivers; 2012 Nov; 9(11):2582-96. PubMed ID: 23161636 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640 [TBL] [Abstract][Full Text] [Related]
27. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Cheng SJ; Thibert L; Sanchez T; Heifets L; Zhang Y Antimicrob Agents Chemother; 2000 Mar; 44(3):528-32. PubMed ID: 10681313 [TBL] [Abstract][Full Text] [Related]
28. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants. Jagadeb M; Rath SN; Sonawane A J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826 [TBL] [Abstract][Full Text] [Related]
29. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Scorpio A; Zhang Y Nat Med; 1996 Jun; 2(6):662-7. PubMed ID: 8640557 [TBL] [Abstract][Full Text] [Related]
30. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. Bhuju S; Fonseca Lde S; Marsico AG; de Oliveira Vieira GB; Sobral LF; Stehr M; Singh M; Saad MH Infect Genet Evol; 2013 Oct; 19():1-6. PubMed ID: 23770140 [TBL] [Abstract][Full Text] [Related]
31. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Kim HJ; Kwak HK; Lee J; Yun YJ; Lee JS; Lee MS; Min SY; Park SK; Kang HS; Maeng YH; Kim SY; Kim SY; Kook YH; Kim YR; Lee KH Int J Tuberc Lung Dis; 2012 Jan; 16(1):98-103. PubMed ID: 22236853 [TBL] [Abstract][Full Text] [Related]
32. Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia. Bwalya P; Yamaguchi T; Mulundu G; Nakajima C; Mbulo G; Solo ES; Fukushima Y; Kasakwa K; Suzuki Y Tuberculosis (Edinb); 2018 Mar; 109():117-122. PubMed ID: 29559115 [TBL] [Abstract][Full Text] [Related]
33. Identification of Novel Efflux Proteins Rv0191, Rv3756c, Rv3008, and Rv1667c Involved in Pyrazinamide Resistance in Mycobacterium tuberculosis. Zhang Y; Zhang J; Cui P; Zhang Y; Zhang W Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584158 [TBL] [Abstract][Full Text] [Related]
34. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Akhmetova A; Kozhamkulov U; Bismilda V; Chingissova L; Abildaev T; Dymova M; Filipenko M; Ramanculov E Int J Tuberc Lung Dis; 2015 Feb; 19(2):179-84. PubMed ID: 25574916 [TBL] [Abstract][Full Text] [Related]
35. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362 [TBL] [Abstract][Full Text] [Related]
36. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 mycobacterium tuberculosis clinical isolates. Mestdagh M; Realini L; Fonteyne PA; Rossau R; Jannes G; Mijs W; DE Smet KA; Portaels F; Van den Eeckhout E Microb Drug Resist; 2000; 6(4):283-7. PubMed ID: 11272256 [TBL] [Abstract][Full Text] [Related]
38. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China. Che Y; Bo D; Lin X; Chen T; He T; Lin Y BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989 [TBL] [Abstract][Full Text] [Related]
39. pncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects. Wu X; Lu W; Shao Y; Song H; Li G; Li Y; Zhu L; Chen C Infect Genet Evol; 2019 Aug; 72():147-150. PubMed ID: 30447296 [TBL] [Abstract][Full Text] [Related]